Login / Signup

A phage-encoded anti-CRISPR enables complete evasion of type VI-A CRISPR-Cas immunity.

Alexander J MeeskeNing JiaAlice K CasselAlbina KozlovaJingqiu LiaoMartin WiedmannDinshaw J PatelLuciano A Marraffini
Published in: Science (New York, N.Y.) (2020)
The CRISPR RNA (crRNA)-guided nuclease Cas13 recognizes complementary viral transcripts to trigger the degradation of both host and viral RNA during the type VI CRISPR-Cas antiviral response. However, how viruses can counteract this immunity is not known. We describe a listeriaphage (ϕLS46) encoding an anti-CRISPR protein (AcrVIA1) that inactivates the type VI-A CRISPR system of Listeria seeligeri Using genetics, biochemistry, and structural biology, we found that AcrVIA1 interacts with the guide-exposed face of Cas13a, preventing access to the target RNA and the conformational changes required for nuclease activation. Unlike inhibitors of DNA-cleaving Cas nucleases, which cause limited immunosuppression and require multiple infections to bypass CRISPR defenses, a single dose of AcrVIA1 delivered by an individual virion completely dismantles type VI-A CRISPR-mediated immunity.
Keyphrases
  • genome editing
  • crispr cas
  • nucleic acid
  • single molecule
  • pseudomonas aeruginosa
  • genome wide
  • dna methylation
  • binding protein
  • cell free
  • circulating tumor
  • transcription factor
  • amino acid